Scholarlink

<p>Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, but its clinical use is limited by serious gastrointestinal and respiratory adverse effects, including constipation, ileus, and pneumonia. The mechanisms linking these complications remain poorly understood. We tested the hypothesis that clozapine disrupts the gut–lung microbiota axis and that this disruption contributes to systemic toxicity. Adult male and female C57BL/6J mice received oral clozapine (5 mg/kg/day) or vehicle for 14 days. Clozapine significantly reduced body weight and fecal output, indicating gastrointestinal hypomotility. 16S rRNA sequencing revealed region-specific and sex-dependent alterations in microbial communities across the lungs, small intestine, cecum, and colon. Untargeted plasma metabolomics identified systemic metabolic changes in both sexes, including increased D-pyroglutamic acid and glutathione, consistent with oxidative and metabolic stress. Correlation analyses demonstrated coordinated associations among reduced fecal output, altered intestinal taxa, and circulating metabolites, indicating disruption of an integrated microbiota–metabolite network. Functionally, clozapine pretreatment significantly decreased survival following lipopolysaccharide-induced acute lung injury, indicating increased pulmonary vulnerability. Together, these findings suggest that clozapine disrupts the gut–lung microbiota–metabolite axis, linking gastrointestinal hypomotility with heightened respiratory susceptibility. This microbiota-centered framework provides mechanistic insight into clozapine-associated systemic toxicity and highlights microbiota-targeted strategies as potential approaches to improve the safety of clozapine therapy in treatment-resistant schizophrenia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clozapine disrupts the gut–lung microbiota axis, linking gastrointestinal hypomotility to increased respiratory vulnerability

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月14日

查看全文
  • Yi Cai,
  • Akifumi Eguchi,
  • Rumi Murayama,
  • Xin Ding,
  • Yong Yue,
  • Tomihisa Niitsu,
  • Yasunori Oda,
  • Takashi Futamura,
  • Jian-Jun Yang,
  • Hiroyuki Nakamura,
  • Kenji Hashimoto

摘要

Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, but its clinical use is limited by serious gastrointestinal and respiratory adverse effects, including constipation, ileus, and pneumonia. The mechanisms linking these complications remain poorly understood. We tested the hypothesis that clozapine disrupts the gut–lung microbiota axis and that this disruption contributes to systemic toxicity. Adult male and female C57BL/6J mice received oral clozapine (5 mg/kg/day) or vehicle for 14 days. Clozapine significantly reduced body weight and fecal output, indicating gastrointestinal hypomotility. 16S rRNA sequencing revealed region-specific and sex-dependent alterations in microbial communities across the lungs, small intestine, cecum, and colon. Untargeted plasma metabolomics identified systemic metabolic changes in both sexes, including increased D-pyroglutamic acid and glutathione, consistent with oxidative and metabolic stress. Correlation analyses demonstrated coordinated associations among reduced fecal output, altered intestinal taxa, and circulating metabolites, indicating disruption of an integrated microbiota–metabolite network. Functionally, clozapine pretreatment significantly decreased survival following lipopolysaccharide-induced acute lung injury, indicating increased pulmonary vulnerability. Together, these findings suggest that clozapine disrupts the gut–lung microbiota–metabolite axis, linking gastrointestinal hypomotility with heightened respiratory susceptibility. This microbiota-centered framework provides mechanistic insight into clozapine-associated systemic toxicity and highlights microbiota-targeted strategies as potential approaches to improve the safety of clozapine therapy in treatment-resistant schizophrenia.